Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
schizophrenia
Pharma
BMS accentuates the positive after Cobenfy trial flop
On the heels of a clinical setback for BMS' schizophrenia newcomer Cobenfy, the company has served up mixed results for 2025's first quarter.
Fraiser Kansteiner
Apr 24, 2025 11:31am
BMS' schizophrenia drug stumbles in blow to blockbuster plan
Apr 23, 2025 10:35am
Teva's subdued outlook puts damper on strong 2024 results
Jan 29, 2025 1:13pm
Lyndra enlists Thermo Fisher for research, manufacturing support
Jan 15, 2025 3:36pm
J&J acquires CNS specialist Intra-Cellular for $14.6B
Jan 13, 2025 10:29am
Even through its remake, Alkermes retains upward trajectory: CEO
Jan 13, 2025 7:36am
